Watanabe N, Yamauchi N, Maeda M, Neda H, Tsuji Y, Okamoto T, Tsuji N, Akiyama S, Sasaki H, Niitsu Y
Department of Internal Medicine (Section 4), Sapporo Medical University, School of Medicine, Japan.
Oncology. 1994 Jul-Aug;51(4):360-5. doi: 10.1159/000227366.
Fifteen patients with advanced solid tumors of various types were treated by the intratumoral administration of recombinant human tumor necrosis factor (rH-TNF). The treatment appeared to benefit the 4 cases of superficial tumors: there were 1 complete response, 1 partial response and 2 minor responses. In all 11 patients with deep-seated tumors, including 6 cases of pancreatic cancer, 4 of liver cell cancer and 1 of metastatic liver tumor, no tumor regression was observed, but progression stopped in all these tumors. Seven of the 11 with deep-seated tumors showed a decrease in tumor markers and/or the development of tumor necrosis. Fever, hypotension and fatigue were the main clinical side effects. No significant changes were found in hematologic, renal or liver parameters. These results suggest that administration of rH-TNF to the tumor site has the potential for controlling local tumor growth.
15例患有各种类型晚期实体瘤的患者接受了瘤内注射重组人肿瘤坏死因子（rH-TNF）治疗。治疗似乎使4例浅表肿瘤患者受益：1例完全缓解，1例部分缓解，2例轻度缓解。在所有11例深部肿瘤患者中，包括6例胰腺癌、4例肝细胞癌和1例转移性肝肿瘤患者，未观察到肿瘤消退，但所有这些肿瘤的进展均停止。11例深部肿瘤患者中有7例肿瘤标志物下降和/或出现肿瘤坏死。发热、低血压和疲劳是主要的临床副作用。血液学、肾脏或肝脏参数未发现明显变化。这些结果表明，在肿瘤部位注射rH-TNF有可能控制局部肿瘤生长。
